Loading…
Loading grant details…
| Funder | European Commission |
|---|---|
| Recipient Organization | Amt Medical Research Bv |
| Country | Netherlands |
| Start Date | Oct 01, 2022 |
| End Date | Sep 30, 2025 |
| Duration | 1,095 days |
| Number of Grantees | 1 |
| Roles | Coordinator |
| Data Source | European Commission |
| Grant ID | 190101904 |
We will revolutionise the medical field by replacing expensive, invasive and high-risk open-heart surgery, with keyhole minimally invasive surgery (MIS) to treat coronary artery disease (CAD).
Our ELANA technology enables reproducible coronary artery bypass grafting (CABG) surgery without the need of heart arrest and suturing, thus avoiding the need to open the patients chest. This is realised with an innovative clip which circumvents the need of suturing of blood vessels altogether.
By realising closed-chest CABG, ELANA reduces not only the risks associated with traditional CABG, such as bleeding, stroke and wound infection, but also significantly shortens recovery times. As a result, ELANA will reduce direct healthcare costs of CABG procedures by over 50%.
To critically de-risk our technological development and accelerate market entry to 2025, AMT Medical seeks a total of 7.5M funding (2.5M grant, 5M equity) to finalise clinical validation and gain market approval.
Amt Medical Research Bv
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant